Read by QxMD icon Read

Roflumilast is no miracle

shared collection
1 papers 0 to 25 followers
By Jason Mann No BS pulmonary critical care fellow
Tsung Yu, Kevin Fain, Cynthia M Boyd, Sonal Singh, Carlos O Weiss, Tianjing Li, Ravi Varadhan, Milo A Puhan
BACKGROUND: Roflumilast, a phosphodiesterase 4 inhibitor, has been approved for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations. It is unclear which patients will have a favourable benefit-harm balance with roflumilast. Our aim was to quantitatively assess the benefits and harms of roflumilast (500 µg/day) compared with placebo. METHODS: We used summary data released by the US Food and Drug Administration to estimate the treatment effects of roflumilast...
July 2014: Thorax
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"